AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+2.9%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$354M
AUM Growth
+$354M
(-9.3%)
Cap. Flow
-$32.3M
Cap. Flow
% of AUM
-9.13%
Top 10 Holdings %
Top 10 Hldgs %
80.31%
Holding
49
New
7
Increased
9
Reduced
4
Closed
5
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$9.09M |
| 2 |
Novo Nordisk
NVO
|
$5.95M |
| 3 |
Viking Therapeutics
VKTX
|
$5.06M |
| 4 |
Revolution Medicines
RVMD
|
$4.35M |
| 5 |
Nuvalent
NUVL
|
$1.58M |
Top Sells
| 1 |
Merck
MRK
|
$54.8M |
| 2 |
Ocular Therapeutix
OCUL
|
$3.42M |
| 3 |
Apogee Therapeutics
APGE
|
$2.3M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$2.04M |
| 5 |
Ionis Pharmaceuticals
IONS
|
$1.28M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNTA
26
Centessa Pharmaceuticals
CNTA
$2.25B
| $1.29M | 0.35% |
+80,380
| New | +$1.29M |
|
27
EyePoint Pharmaceuticals
EYPT
$797M
| $1.25M | 0.34% |
156,300
+54,800
| +54% | +$438K |
|
28
Charles River Laboratories
CRL
$8.04B
| $1.24M | 0.34% |
6,305
-600
| -9% | -$118K |
|
|
29
Ionis Pharmaceuticals
IONS
$6.8B
| $1.22M | 0.33% |
30,479
-32,000
| -51% | -$1.28M |
|
30
Keros Therapeutics
KROS
$618M
| $1.16M | 0.32% |
20,000
| – | – |
|
31
Kura Oncology
KURA
$686M
| $1.12M | 0.3% |
57,178
| – | – |
|
32
Ascendis Pharma
ASND
$11.8B
| $1.11M | 0.3% |
7,440
| – | – |
|
33
Annexon
ANNX
$226M
| $1.02M | 0.28% |
172,226
+24,741
| +17% | +$146K |
|
34
Corbus Pharmaceuticals
CRBP
$115M
| $978K | 0.27% |
47,400
+27,400
| +137% | +$565K |
|
|
SLN
35
Silence Therapeutics
SLN
$227M
| $954K | 0.26% |
52,476
| – | – |
|
36
Syndax Pharmaceuticals
SNDX
$1.41B
| $929K | 0.25% |
48,263
| – | – |
|
37
NewAmsterdam Pharma
NAMS
$2.71B
| $901K | 0.25% |
54,285
| – | – |
|
38
Alector
ALEC
$238M
| $901K | 0.25% |
+193,317
| New | +$901K |
|
39
Disc Medicine
IRON
$2.07B
| $660K | 0.18% |
13,440
| – | – |
|
40
Larimar Therapeutics
LRMR
$310M
| $593K | 0.16% |
90,490
| – | – |
|
|
SLRN
41
DELISTED
ACELYRIN
SLRN
| $459K | 0.13% |
+93,114
| New | +$459K |
|
42
Madrigal Pharmaceuticals
MDGL
$9.76B
| $330K | 0.09% |
1,557
| – | – |
|
43
Summit Therapeutics
SMMT
$17.6B
| $318K | 0.09% |
+14,512
| New | +$318K |
|
44
Q32 Bio
QTTB
$20.9M
| $210K | 0.06% |
+4,705
| New | +$210K |
|
|
45
Apogee Therapeutics
APGE
$2.17B
| – | – |
-58,400
| Closed | -$2.3M |
|
|
46
Merck
MRK
$210B
| – | – |
-442,504
| Closed | -$54.8M |
|
|
47
Ocular Therapeutix
OCUL
$2.12B
| – | – |
-500,000
| Closed | -$3.42M |
|
48
Pliant Therapeutics
PLRX
$101M
| – | – |
-50,000
| Closed | -$538K |
|
49
Sarepta Therapeutics
SRPT
$1.78B
| – | – |
-2,600
| Closed | -$411K |
|